Hyoscyamine Alternatives Compared
Hyoscyamine | Entyvio | Remicade |
|
---|
Hyoscyamine | Entyvio (vedolizumab) | Remicade (infliximab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Hyoscyamine may be used in the treatment of a wide variety of gastrointestinal problems including cramps, bladder control issues, and irritable bowel syndrome. Drowsiness and dry mouth are common... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Crohn's Disease - Active, Ankylosing Spondylitis, Inflammatory Bowel Disease, Crohn's Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative... View more |
Related suggestions Crohn's Disease
|
|||||||||||||||||||||||
More about Hyoscyamine | More about Entyvio (vedolizumab) | More about Remicade (infliximab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Hyoscyamine has an average rating of 7.8 out of 10 from a total of 111 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 16% reported a negative effect. |
Entyvio has an average rating of 6.1 out of 10 from a total of 153 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Remicade has an average rating of 7.1 out of 10 from a total of 207 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: hyoscyamine side effects in more detail. |
See also: Entyvio side effects in more detail. |
See also: Remicade side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all hyoscyamine prices |
View all Entyvio prices |
View all Remicade prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Anaspaz, Ed-Spaz, Hyosyne, Levbid, Levsin, Levsin SL, NuLev, Oscimin, Symax Duotab, Symax SL, Symax SR View more | Other vedolizumab brands include: Entyvio Pen | Other infliximab brands include: Avsola, Inflectra, Ixifi, Renflexis, Zymfentra | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
600 hours |
228 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 206 drugs are known to interact with hyoscyamine:
|
A total of 152 drugs are known to interact with Entyvio:
|
A total of 498 drugs are known to interact with Remicade:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
May 20, 2014 |
August 24, 1998 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.